These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 9025736

  • 1. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
    Vallabhajosula S, Hirschowitz J, Machac J.
    J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
    [Abstract] [Full Text] [Related]

  • 2. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S, Tatsch K, Dähne I, Mager T, Scherer J, Hahn K.
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [Abstract] [Full Text] [Related]

  • 3. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [Abstract] [Full Text] [Related]

  • 4. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ.
    Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
    [Abstract] [Full Text] [Related]

  • 5. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M, Krack P, Franz M, Klett R, Bauer R, Gallhofer B, Dorndorf W.
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [Abstract] [Full Text] [Related]

  • 6. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Volk S, Maul FD, Hör G, Schreiner M, Weppner M, Holzmann T, Pflug B.
    Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
    [Abstract] [Full Text] [Related]

  • 7. [123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects.
    Schlösser R, Schlegel S, Hiemke C, Nickel O, Bockisch A, Rao ML, Hahn K.
    Psychiatry Res; 1997 Sep 29; 75(2):103-14. PubMed ID: 9351492
    [Abstract] [Full Text] [Related]

  • 8. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brücke T, Kasper S.
    Psychopharmacology (Berl); 1999 Jan 29; 141(2):175-81. PubMed ID: 9952042
    [Abstract] [Full Text] [Related]

  • 9. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M, Parellada E, Lomeña F, Catafau AM, Font M, Gómez JC, López-Carrero C, Gutiérrez F, Pavía J, Salamero M.
    Psychiatry Res; 2001 Aug 25; 107(2):87-97. PubMed ID: 11530275
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB, Bartenstein P, Schober O, Oberwittler C, Lerch H, Masur H.
    Nuklearmedizin; 1994 Oct 25; 33(5):184-8. PubMed ID: 7997375
    [Abstract] [Full Text] [Related]

  • 11. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C, Toska K, Friberg L, Holm S, Angelo HR, Knudsen GM.
    J Cereb Blood Flow Metab; 2001 Jan 25; 21(1):92-7. PubMed ID: 11149673
    [Abstract] [Full Text] [Related]

  • 12. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W, Grundmann M, Huber G.
    Radiologe; 1995 Nov 25; 35(11):838-43. PubMed ID: 8657887
    [Abstract] [Full Text] [Related]

  • 13. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD, Abrams DN, Greenberg CR, Hobson D.
    J Nucl Med; 1996 Oct 25; 37(10):1589-91. PubMed ID: 8862288
    [Abstract] [Full Text] [Related]

  • 14. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
    Kasper S, Tauscher J, Küfferle B, Barnas C, Hesselmann B, Asenbaum S, Podreka I, Brücke T.
    Psychopharmacology (Berl); 1998 Apr 25; 136(4):367-73. PubMed ID: 9600582
    [Abstract] [Full Text] [Related]

  • 15. Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia.
    Geaney DP, Ellis PM, Soper N, Shepstone BJ, Cowen PJ.
    Biol Psychiatry; 1992 Aug 01; 32(3):293-5. PubMed ID: 1358229
    [No Abstract] [Full Text] [Related]

  • 16. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S, Farde L, Halldin C.
    Arch Gen Psychiatry; 1997 Oct 01; 54(10):953-8. PubMed ID: 9337776
    [Abstract] [Full Text] [Related]

  • 17. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
    Oliver DW, Dormehl IC, Van der Schyf CJ, Neumeyer JL, Hugo N, Keeve R, Rossouw NT, Müller-Gärtner HW, Castagnoli N.
    Arzneimittelforschung; 1997 Jun 01; 47(6):692-9. PubMed ID: 9239444
    [Abstract] [Full Text] [Related]

  • 18. SPECT studies of D2 occupancy in low-dose haloperidol treatment.
    Hirschowitz J, Hitzemann R, Vallabhajosula S.
    Am J Psychiatry; 1997 May 01; 154(5):715-6. PubMed ID: 9137141
    [No Abstract] [Full Text] [Related]

  • 19. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.
    Schlegel S, Schlösser R, Hiemke C, Nickel O, Bockisch A, Hahn K.
    Psychopharmacology (Berl); 1996 Apr 01; 124(3):285-7. PubMed ID: 8740053
    [Abstract] [Full Text] [Related]

  • 20. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
    Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA.
    Psychiatry Res; 1999 Nov 08; 92(1):33-44. PubMed ID: 10688158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.